PTCT Stock Overview
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders.
PTC Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$49.16|
|52 Week High||US$55.58|
|52 Week Low||US$25.01|
|1 Month Change||-7.39%|
|3 Month Change||22.23%|
|1 Year Change||25.12%|
|3 Year Change||42.00%|
|5 Year Change||145.68%|
|Change since IPO||198.12%|
Recent News & Updates
PTC Therapeutics betas topline expectations, strengthens commercial portfolio
PTC Therapeutics (NASDAQ:PTCT) shows a 42% growth in revenue to $166M. Revenue includes net product revenue across the commercial portfolio of $143.7M vs. $103.1M last year. Royalty revenue of $21.8M vs. $13.6M. Bifurcating: Translarna net product revenues were $77M vs. $52.6M; Emflaza net product revenues were $56.8M vs. $49.1M. GAAP R&D expenses were $157.3M vs. $125.5M; GAAP SG&A expenses were $79.9M vs. $68.9M. Net loss was $152.1M vs. $118.4M. Cash, cash equivalents, and marketable securities was $505.5M on June 30, 2022, compared to $773.4M on Dec. 31, 2021. Reaffirms FY guidance: Total revenues between $700M-750M; net product revenues for the DMD franchise between $475M-495M. R&D and SG&A expense for the full year 2022 to be between $915M-965M. GAAP EPS of -$2.13 misses consensus by $0.76. "We made significant progress in the second quarter toward achieving our ambitious goals for 2022. We continued to generate strong revenue growth, to expand our product portfolio, and to advance our pipeline. PTC has a broad and deep pipeline across a range of diseases, and we eagerly anticipate important results for several registration-directed studies during the next six to twelve months and this will continue our transformational growth." said Stuart W. Peltz, Ph.D., CEO. Stock gets a sell-side rating of Buy with 3.63 score and price target of $49.9. Quant rating of Hold with lowest factor grades to valuation and growth. Contributor who gives sell rating to the stock writes: 'DMD Trial News Unlikely To Restore Flagging Share Price' Previously: PTC Therapeutics Q2 GAAP EPS misses, revenue beats, FY22 guidance reaffirmed (Aug. 4)
|PTCT||US Biotechs||US Market|
Return vs Industry: PTCT exceeded the US Biotechs industry which returned -30.9% over the past year.
Return vs Market: PTCT exceeded the US Market which returned -21.6% over the past year.
|PTCT Average Weekly Movement||5.4%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.9%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: PTCT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: PTCT's weekly volatility (5%) has been stable over the past year.
About the Company
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil.
PTC Therapeutics Fundamentals Summary
|PTCT fundamental statistics|
Is PTCT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PTCT income statement (TTM)|
|Cost of Revenue||US$575.99m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-7.77|
|Net Profit Margin||-89.89%|
How did PTCT perform over the long term?See historical performance and comparison
Is PTCT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PTCT?
Other financial metrics that can be useful for relative valuation.
|What is PTCT's n/a Ratio?|
Price to Sales Ratio vs Peers
How does PTCT's PS Ratio compare to its peers?
|PTCT PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
BPMC Blueprint Medicines
DNLI Denali Therapeutics
FOLD Amicus Therapeutics
ARWR Arrowhead Pharmaceuticals
PTCT PTC Therapeutics
Price-To-Sales vs Peers: PTCT is good value based on its Price-To-Sales Ratio (5.7x) compared to the peer average (17.2x).
Price to Earnings Ratio vs Industry
How does PTCT's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: PTCT is good value based on its Price-To-Sales Ratio (5.7x) compared to the US Biotechs industry average (13x)
Price to Sales Ratio vs Fair Ratio
What is PTCT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||5.7x|
|Fair PS Ratio||2.8x|
Price-To-Sales vs Fair Ratio: PTCT is expensive based on its Price-To-Sales Ratio (5.7x) compared to the estimated Fair Price-To-Sales Ratio (2.8x).
Share Price vs Fair Value
What is the Fair Price of PTCT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: PTCT ($49.16) is trading below our estimate of fair value ($244.63)
Significantly Below Fair Value: PTCT is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
How is PTC Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PTCT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PTCT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PTCT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PTCT's revenue (11.9% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: PTCT's revenue (11.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PTCT is forecast to be unprofitable in 3 years.
Discover growth companies
How has PTC Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PTCT is currently unprofitable.
Growing Profit Margin: PTCT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PTCT is unprofitable, and losses have increased over the past 5 years at a rate of 37.9% per year.
Accelerating Growth: Unable to compare PTCT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PTCT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: PTCT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Discover strong past performing companies
How is PTC Therapeutics's financial position?
Financial Health Score1/6
Financial Health Score 1/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: PTCT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: PTCT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: PTCT has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: PTCT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PTCT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if PTCT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
What is PTC Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PTCT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PTCT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PTCT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PTCT's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as PTCT has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Stuart Peltz (62 yo)
Dr. Stuart W. Peltz, Ph D., co-founded PTC Therapeutics Inc. in 1998 and has been its Chief Executive Officer since 1998. Dr. Peltz has been Independent Director of Health Sciences Acquisitions Corporation...
CEO Compensation Analysis
Compensation vs Market: Stuart's total compensation ($USD11.02M) is above average for companies of similar size in the US market ($USD6.80M).
Compensation vs Earnings: Stuart's compensation has increased whilst the company is unprofitable.
Experienced Management: PTCT's management team is considered experienced (3.5 years average tenure).
Experienced Board: PTCT's board of directors are seasoned and experienced ( 16.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: PTCT insiders have only sold shares in the past 3 months.
Recent Insider Transactions
|09 Aug 22||SellUS$118,522||Stephanie Okey||Individual||2,296||US$51.62|
|09 Jun 22||SellUS$20,074||Dawn Svoronos||Individual||738||US$27.20|
|07 Jun 22||SellUS$10,919||Stuart Peltz||Individual||407||US$26.83|
|19 Apr 22||SellUS$34,947||Eric Pauwels||Individual||822||US$42.52|
|19 Apr 22||SellUS$38,136||Matthew Klein||Individual||897||US$42.52|
|14 Apr 22||SellUS$3,713||Stuart Peltz||Individual||82||US$45.28|
|01 Feb 22||SellUS$25,281||Neil Almstead||Individual||632||US$40.00|
|01 Feb 22||SellUS$89,724||Stuart Peltz||Individual||2,243||US$40.00|
|01 Feb 22||SellUS$31,162||Mark Boulding||Individual||779||US$40.00|
|01 Feb 22||SellUS$14,681||Eric Pauwels||Individual||367||US$40.00|
|01 Feb 22||SellUS$12,521||Christine Utter||Individual||313||US$40.00|
|01 Feb 22||SellUS$22,121||Emily Hill||Individual||553||US$40.00|
|25 Jan 22||SellUS$8,295||Emily Hill||Individual||211||US$39.31|
|25 Jan 22||SellUS$1,691||Neil Almstead||Individual||43||US$39.31|
|25 Jan 22||SellUS$12,974||Stuart Peltz||Individual||330||US$39.31|
|25 Jan 22||SellUS$14,114||Eric Pauwels||Individual||359||US$39.31|
|07 Jan 22||SellUS$19,648||Dawn Svoronos||Individual||510||US$38.53|
|07 Jan 22||SellUS$30,820||Emily Hill||Individual||800||US$38.53|
|07 Jan 22||SellUS$34,095||Mark Boulding||Individual||885||US$38.53|
|07 Jan 22||SellUS$28,778||Christine Utter||Individual||747||US$38.53|
|07 Jan 22||SellUS$30,859||Neil Almstead||Individual||801||US$38.53|
|07 Jan 22||SellUS$29,857||Matthew Klein||Individual||775||US$38.53|
|07 Jan 22||SellUS$83,330||Stuart Peltz||Individual||2,163||US$38.53|
|07 Jan 22||SellUS$33,363||Eric Pauwels||Individual||866||US$38.53|
|04 Jan 22||SellUS$15,559||Stuart Peltz||Individual||378||US$41.16|
|04 Jan 22||SellUS$7,121||Emily Hill||Individual||173||US$41.16|
|04 Jan 22||SellUS$33,177||Eric Pauwels||Individual||806||US$41.16|
|04 Jan 22||SellUS$2,634||Neil Almstead||Individual||64||US$41.16|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
PTC Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: PTC Therapeutics, Inc.
- Ticker: PTCT
- Exchange: NasdaqGS
- Founded: 1998
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$3.517b
- Shares outstanding: 71.54m
- Website: https://www.ptcbio.com
Number of Employees
- PTC Therapeutics, Inc.
- 100 Corporate Court
- South Plainfield
- New Jersey
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PTCT||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jun 2013|
|BH3||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jun 2013|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/23 00:00|
|End of Day Share Price||2022/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.